Clinical trial
A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at…
NCT05256134 · Hoffmann-La Roche, Industry · Terminated
Key facts
| NCT number | NCT05256134 |
|---|---|
| Title | A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD) |
| Official title | A Phase III, Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease |
| Acronym | SKYLINE |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Alzheimers Disease |
| Intervention type | Drug |
| Interventions | Gantenerumab, Placebo |
| Enrollment | 25 |
| Start date | Apr 19, 2022 |
| Primary completion | Mar 13, 2023 |
| Completion | Mar 13, 2023 |
| First posted | Feb 25, 2022 |
| Last update posted | Jun 12, 2025 |
| Countries | Argentina, Australia, Canada, Italy, Poland, South Korea, Spain, Sweden, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: